Fonar Corp (FONR)
16.62
+0.42
(+2.59%)
USD |
NASDAQ |
Apr 23, 10:40
Fonar Cash and Short Term Investments (Quarterly): 53.26M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 53.26M |
September 30, 2023 | 51.73M |
June 30, 2023 | 51.31M |
March 31, 2023 | 49.67M |
December 31, 2022 | 49.54M |
September 30, 2022 | 48.73M |
June 30, 2022 | 48.76M |
March 31, 2022 | 46.04M |
December 31, 2021 | 44.88M |
September 30, 2021 | 43.44M |
June 30, 2021 | 44.49M |
March 31, 2021 | 40.84M |
December 31, 2020 | 40.61M |
September 30, 2020 | 38.80M |
June 30, 2020 | 36.83M |
March 31, 2020 | 31.05M |
December 31, 2019 | 30.69M |
September 30, 2019 | 29.01M |
June 30, 2019 | 28.98M |
March 31, 2019 | 24.78M |
December 31, 2018 | 23.29M |
September 30, 2018 | 21.19M |
June 30, 2018 | 19.63M |
March 31, 2018 | 15.41M |
December 31, 2017 | 14.19M |
Date | Value |
---|---|
September 30, 2017 | 11.34M |
June 30, 2017 | 10.14M |
March 31, 2017 | 7.75M |
December 31, 2016 | 7.692M |
September 30, 2016 | 7.994M |
June 30, 2016 | 8.528M |
March 31, 2016 | 13.15M |
December 31, 2015 | 12.95M |
September 30, 2015 | 10.97M |
June 30, 2015 | 9.449M |
March 31, 2015 | 7.828M |
December 31, 2014 | 11.67M |
September 30, 2014 | 10.66M |
June 30, 2014 | 9.952M |
March 31, 2014 | 9.589M |
December 31, 2013 | 9.425M |
September 30, 2013 | 9.238M |
June 30, 2013 | 7.871M |
March 31, 2013 | 9.243M |
December 31, 2012 | 14.76M |
September 30, 2012 | 12.90M |
June 30, 2012 | 12.03M |
March 31, 2012 | 11.04M |
December 31, 2011 | 9.941M |
September 30, 2011 | 9.54M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
28.98M
Minimum
Jun 2019
53.26M
Maximum
Dec 2023
42.56M
Average
44.49M
Median
Jun 2021
Cash and Short Term Investments (Quarterly) Benchmarks
XWELL Inc | 23.05M |
ProPhase Labs Inc | 4.736M |
Applied DNA Sciences Inc | 3.359M |
Veracyte Inc | 216.45M |
OncoCyte Corp | 9.432M |